Table 1.
Patient baseline characteristics.
| Variable | Overall N = 40 (%) |
|---|---|
| Median age (range) | 72 (54–86) |
| Median Gleason score at diagnosis, (IQR) | 8 (7–9) |
| Median alkaline phosphatase (U/L), (IQR) | 107 (70–241) |
| Median haemoglobin (g/L), (IQR) | 11.6 (10.8–12.4) |
| Median PSA (µg/L), (IQR) | 66.1 (21.5–125.2) |
| ECOG performance status | |
| 0 | 17 (42.5) |
| 1 | 19 (47.5) |
| 2 | 4 (10.0) |
| Previous treatment | |
| Radical prostatectomy or radiotherapy | 23 (57.5) |
| Abiraterone/enzalutamide | 31 (77.5) |
| Docetaxel | 31 (77.5) |
| Cabazitaxel | 25 (62.5) |
| Palliative-intent radiotherapy | 25 (62.5) |
| Site of disease on PSMA PET/CT | |
| Bone | 38 (95.0) |
| Nodal | 25 (62.5) |
| Visceral | 9 (22.5) |
| Pain at baseline | |
| No pain | 9 (22.5) |
| Mild | 14 (35.0) |
| Moderate | 14 (35.0) |
| Severe | 3 (7.5) |
| AR status | |
| AR normal | 25 (62.5) |
| AR amplified | 15 (37.5) |